Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.
about
Dabigatran approaching the realm of heparin-induced thrombocytopeniaEffective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulantsNon-vitamin K antagonist oral anticoagulants and antiphospholipid syndromePreventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants.Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.Intravenous thrombolysis in a patient using factor Xa inhibitor.Emergency reversal of dabigatran for emergency surgery.Determination of rivaroxaban in patient's plasma samples by anti-Xa chromogenic test associated to High Performance Liquid Chromatography tandem Mass Spectrometry (HPLC-MS/MS).Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?Direct oral anticoagulant drug level testing in clinical practice: A single institution experience.Rivaroxaban and hemostasis in emergency care.Monitoring target specific anticoagulants.Management of venous thromboembolism--controversies and the future.Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban.Novel oral anticoagulants in cardiovascular disease.Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.Dabigatran excess: case report and review of the literature.Perioperative management of oral anticoagulants: a focus on target-specific oral anticoagulants.Management of peri-operative anti-thrombotic therapy.Assessing nonvitamin K antagonist oral anticoagulants (NOACs) in the laboratory.Dose tailoring of dabigatran etexilate: obvious or excessive?Laboratory measurement of the direct oral anticoagulants.The laboratory's 2015 perspective on direct oral anticoagulant testing.Comparison of different laboratory tests in the evaluation of hemorrhagic risk of patients using rivaroxaban in the critical care setting: diagnostic accuracy study.Main considerable factors for correct laboratory test interpretation under DOA treatment.Relation between frequency of activated partial prothrombin time measurements and clinical outcomes in patients after initiation of dabigatran: A two-center cooperative study.More on normal prothrombin times in the presence of therapeutic levels of rivaroxaban--early experience from King's College Hospital.Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels.Normal prothrombin time in the presence of therapeutic levels of rivaroxaban.Effects of rivaroxaban on routine coagulation screening tests using commonly used reagents.Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology.Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL.The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders.Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban: Can This Test Be Used to Quantify Drug Level?The anticoagulant effect of therapeutic levels of dabigatran in atrial fibrillation evaluated by thrombelastography (TEG®), Hemoclot Thrombin Inhibitor (HTI) assay and Ecarin Clotting Time (ECT).A performance evaluation of a novel human recombinant tissue factor prothrombin time reagent (Revohem™ PT).Standardized use of novel oral anticoagulants plasma level thresholds in a new thrombolysis decision making protocol.Dabigatran deliberate overdose: two cases and suggestions for laboratory monitoring.Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation.A Practical Review of the Emerging Direct Anticoagulants, Laboratory Monitoring, and Reversal Agents.
P2860
Q26744261-9EDF2BBA-017C-49C6-997C-617369BD679AQ26746213-534EEED1-C3A9-400B-92C5-4AFB62E5596DQ28067420-71741F46-F456-4E16-A282-CCC29BFC4C5AQ33854667-F4E50421-A464-4F66-BB44-66BF9A94D67BQ34206252-4469BD0F-A63D-46C9-8D80-4AF0CE34CC32Q34300323-F22FDFAF-A078-4517-B8EF-A3763936A290Q35578443-251223A7-EC0D-4203-8068-D32D4DAAC34BQ36272889-4354F0F9-91C0-4873-8ADC-6311D75BB376Q36331126-9140F5E5-7B4C-48E0-861F-0B565BEF5E11Q37037385-9C9A3CF6-9857-4E32-9F70-DB7727635D54Q37631564-47F0EDCE-FF74-4BC0-A7EC-EA8387D4F1F7Q38079153-7258AE10-2493-477E-B33D-8378D846D943Q38093286-B94FCEEA-8E15-4F1E-846E-28EDC0C2BDCAQ38128366-3B3ACD30-D9F8-4C9B-9CA1-3F4A758DB39EQ38137852-3615BE95-D484-49AC-AFA8-773EA21F855AQ38178891-F0E0228E-A716-43BD-B145-EDBADB73FB62Q38241091-843C7D6A-1DD2-437B-BD5C-341B07B557D9Q38254247-C4A492F4-9DEB-4F2B-B348-C73CEE1FD963Q38273789-6A56D517-4631-4D7C-8D17-1E293E10FD45Q38481929-0C6A0C61-9C68-4421-93AD-1BE5F3A8177CQ38494667-5B91DFB2-FC8B-41FA-BDE8-B373B715C179Q38613869-A4B77134-F899-4ADE-81A4-59CE93EEDFEEQ38704892-639057BC-0A11-4A8C-837C-70880C988385Q41413847-1884C145-2BA8-4A87-8766-8202D792BFF7Q42862770-5A668C08-29F7-4616-B691-7235971BD635Q42868367-A6913568-D897-4443-BA1F-785B57B016A8Q43990034-E0126C3B-4258-4456-8596-4E85B00AAE41Q44695044-62DB697A-0E62-4626-A778-262A23E23B5DQ44834107-E8B061C1-9409-4723-91DA-18B1C7C50D05Q45856076-E9AB706F-BCD4-46D4-861B-5220E34295AAQ45865979-EA01D4C0-09FD-4813-A1AB-D17ED03A2C27Q45874001-0C2C2A36-A182-4F80-AEF1-D323995BDDC0Q45879084-44FD5841-3737-436F-ACFD-341BDF9F5102Q46702658-315D9C01-E665-43CA-B146-F0E3949C61A2Q47204779-4B3E9378-419C-4058-A108-94FDA75489B4Q48028227-47F8DACB-B81A-418A-BB77-5E6FD4EACB41Q48163723-F335126C-A60C-4A7B-8277-B120C60B17DEQ48889301-610974C7-E477-4640-AFD3-2794A1C7B9B7Q49563307-5311E329-8B4A-416D-B008-CCF97A914234Q50034024-FC45750B-663C-4DA9-8D1C-385C115BDDC2
P2860
Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Effects on routine coagulation ...... for Standards in Haematology.
@ast
Effects on routine coagulation ...... for Standards in Haematology.
@en
Effects on routine coagulation ...... for Standards in Haematology.
@nl
type
label
Effects on routine coagulation ...... for Standards in Haematology.
@ast
Effects on routine coagulation ...... for Standards in Haematology.
@en
Effects on routine coagulation ...... for Standards in Haematology.
@nl
prefLabel
Effects on routine coagulation ...... for Standards in Haematology.
@ast
Effects on routine coagulation ...... for Standards in Haematology.
@en
Effects on routine coagulation ...... for Standards in Haematology.
@nl
P2093
P356
P1476
Effects on routine coagulation ...... for Standards in Haematology.
@en
P2093
David Keeling
Steve Kitchen
Trevor Baglin
P304
P356
10.1111/BJH.12052
P407
P577
2012-09-13T00:00:00Z